🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Cathie Wood's ARK trades Incyte, Recursion stock, buys Blade Air Mobility

EditorLina Guerrero
Published 07/09/2024, 08:25 PM
INCY
-
ZM
-
ZI
-
PSNY
-

Cathie Wood's ARK ETF published their daily trades for Tuesday, July 9th, 2024, showcasing a series of strategic moves within the tech and healthcare sectors. The trades indicate ARK's continued confidence in certain companies while reducing positions in others.

Topping the list with the highest dollar-value trade, ARK's ARKG ETF sold a significant holding of 51,641 shares in INCYTE CORP (NASDAQ:INCY), equating to approximately $3,003,956. This move follows a pattern of selling INCYTE shares, as the fund also reduced its position on Monday, July 8th, and Friday, July 5th, 2024, suggesting a bearish outlook on the biopharmaceutical company.

Conversely, ARK showed a bullish stance on RECURSION PHARMACEUTICALS INC (NASDAQ:RXRX), purchasing a total of 143,193 shares across its ARKK and ARKG ETFs, valued at $1,059,628. This follows a consistent buying trend, with ARK accumulating shares of RECURSION PHARMACEUTICALS throughout the past week.

Another notable purchase was BLADE AIR MOBILITY INC (NASDAQ:BLDE), with ARKQ ETF acquiring 177,289 shares totaling $611,647. The investment in the urban air mobility company is a continuation of ARK's interest in the aerospace sector, as seen with previous trades in BLADE AIR MOBILITY throughout the first week of July.

On the sell side, ARK's ARKK ETF parted with 909 shares of GINKGO BIOWORKS HOLDINGS INC (NYSE:DNA) for a modest $309, and ARKW ETF sold 47 shares of TELADOC HEALTH INC (NYSE:TDOC) at $435. These small-scale sales contrast with the larger divestment from TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD (NYSE:TSM), where ARKW ETF sold 3,995 shares, resulting in $745,586.

ARK also engaged in buying PACIFIC BIOSCIENCES OF CALIFORNIA INC (NASDAQ:PACB), PERSONALIS INC (NASDAQ:PSNL), TEMPUS AI INC (NASDAQ:TEM), and VERACYTE INC (NASDAQ:VCYT), with total dollar values of $227,213, $117,023, $709,318, and $724,063, respectively. These purchases reflect ARK's continued focus on genomic and biotech companies.

In the realm of sales, ARK's ARKK and ARKG ETFs sold a combined total of 75,932 shares of VERVE THERAPEUTICS INC (NASDAQ:VERV) for $430,534, and ARKK ETF sold 35,563 shares of ZOOM VIDEO COMMUNICATIONS INC (NASDAQ:ZM) with a dollar value of $2,041,316, indicating a pivot away from these stocks.

The daily trades provide a window into ARK's investment strategy, highlighting a mix of divestments and acquisitions that reflect the fund's dynamic approach to portfolio management. Investors and market watchers will closely monitor these moves to gauge ARK's outlook on the evolving market landscape.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.